Synthomer (LON:SYNT) Full Year 2023 Results
Key Financial Results
-
Revenue: UK£1.97b (down 17% from FY 2022).
-
Net loss: UK£102.5m (loss widened by 304% from FY 2022).
-
UK£1.20 loss per share (further deteriorated from UK£1.09 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Synthomer Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates by 133%.
Looking ahead, revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 3.4% decline forecast for the Chemicals industry in the United Kingdom.
Performance of the British Chemicals industry.
The company’s shares are up 52% from a week ago.
Risk Analysis
Before we wrap up, we’ve discovered 3 warning signs for Synthomer that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
